Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)

Project Information

TUDCA-ALS

Grant agreement ID: 755094

DOI 10.3030/755094

Project closed

EC signature date 15 November 2017

Start date 1 January 2018

End date 31 December 2023

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 5 596 928,00

EU contribution € 5 596 928,00

Coordinated by

HUMANITAS MIRASOLE SPA
Italy

Deliverables

Documents, reports (1)

Dissemination and exploitation plan

Dissemination and Exploitation Plan. The document will describe the dissemination and exploitation strategies and action plan (Month 3

Websites, patent fillings, videos etc. (1)

Project website

Project website. The report will include the characteristics of the website, the activities involved for its creation and print screens of the website pages (Month 6

Publications

Peer reviewed articles (6)

Review of disease-modifying drug trials in amyotrophic lateral sclerosis

Author(s): Paolo Tornese; Stefania Lalli; Antoniangela Cocco; Alberto Albanese
Published in: Journal of Neurology Neurosurgery and Psychiatry, Issue 3, 2022, Page(s) 521-529, ISSN 0022-3050
Publisher: BMJ Publishing Group
DOI: 10.1136/jnnp-2021-328470

Tauro-Urso-Deoxycholic Acid Trials in Amyotrophic Lateral Sclerosis: What is Achieved and What to Expect

Author(s): Maria Lo Giudice, Antoniangela Cocco, Giorgio Reggiardo, Stefania Lalli, Alberto Albanese
Published in: Clinical Drug Investigation, 2023, ISSN 1179-1918
Publisher: Springer
DOI: 10.1007/s40261-023-01324-0

Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases

Author(s): Kareem Khalaf; Paolo Tornese; Antoniangela Cocco; Alberto Albanese
Published in: Translational Neurodegeneration, Issue 3, 2022, Page(s) 33, ISSN 2047-9158
Publisher: Springer Nature
DOI: 10.1186/s40035-022-00307-z

A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial

Author(s): Flavia L Lombardo, Stefania Spila Alegiani, Flavia Mayer, Marta Cipriani, Maria Lo Giudice, Albert Christian Ludolph, Christopher J McDermott, Philippe Corcia, Philip Van Damme, Leonard H Van den Berg, Orla Hardiman, Gabriele Nicolini, Nicola Vanacore, Brian Dickie, Alberto Albanese, Maria Puopolo; TUDCA-ALS Study Group (Paolo Tornese, Antoniangela Cocco, Michela Matteoli, Eliana Lauranzano, Maria
Published in: Trials, 2023, ISSN 1745-6215
Publisher: BioMed Central
DOI: 10.1186/s13063-023-07638-w

Cox regression and survival analysis from the tauro-urso-deoxycholic trial in amyotrophic lateral sclerosis

Author(s): Giorgio Reggiardo; Maria Lo Giudice; Stefania Lalli; Gilberto Rinaldi; Alberto Albanese
Published in: Frontiers in Neurology, Issue 5, 2023, ISSN 1664-2295
Publisher: Frontiers Research Foundation
DOI: 10.3389/fneur.2023.1163855

Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol

Author(s): Alberto Albanese, Albert Christian Ludolph, Christopher J McDermott, Philippe Corcia, Philip Van Damme, Leonard H Van den Berg, Orla Hardiman, Gilberto Rinaldi, Nicola Vanacore, Brian Dickie, TUDCA-ALS Study Group (Tornese Paolo, Cocco Antoniangela, Lo Giudice Maria, Matteoli Michela, Lauranzano Eliana, Malosio Maria Luisa, Adriana Elia Chiara, Lombardo Flavia, Mayer Flavia, Puopolo Maria, Alegian
Published in: Frontiers in Neurology, Issue 16642295, 2022, ISSN 1664-2295
Publisher: Frontiers Research Foundation
DOI: 10.3389/fneur.2022.1009113